On Friday, Piper Sandler reaffirmed its Overweight rating and $100.00 price target on Nuvalent (NASDAQ:NUVL), a clinical-stage biopharmaceutical company. The firm's analyst highlighted expectations for the upcoming presentation of clinical data at the ESMO Congress, scheduled for September 13-17. Nuvalent is anticipated to provide updates on its next-generation, selective ROS1 inhibitor, zidesamtinib, and its next-generation, selective ALK inhibitor, NVL-655.
The analyst noted that initial data have shown positive safety and efficacy response rates for both zidesamtinib and NVL-655. Updated data expected at the ESMO Congress are believed to further confirm the durability benefits, such as duration of response (DOR) and progression-free survival (PFS), for these treatments. The compounds are currently in the Phase 1 portions of the ARROS-1 and ALKOVE-1 clinical trials.
Patients enrolled in these trials are described as highly refractory, meaning they have not responded well to previous treatments. Due to the lack of directly comparable patient populations, it is challenging to define a clear success benchmark for the evaluations. However, the firm emphasized the importance of sub-population analyses, which consider factors such as line of therapy and mutational status, in assessing the results.
In other recent news, Nuvalent, a company specializing in cancer therapies, has made significant strides in its developmental endeavors. Barclays (LON:BARC) has initiated coverage on Nuvalent stock, assigning an Overweight rating and a price target of $100, based on the company's upcoming milestones and data readouts. Nuvalent is set to present Phase 1 data for its ALK inhibitor, NVL-655, at the European Society for Medical Oncology conference, a development eagerly awaited by the medical community and investors.
In addition, Nuvalent announced the start of a Phase 1a/1b clinical trial for NVL-330, a new drug candidate for HER2-altered non-small cell lung cancer. The trial aims to establish the safety and efficacy of NVL-330.
The company also announced the promotion of Henry Pelish, Ph.D., to the position of Chief Scientific Officer, affirming his significant role in guiding Nuvalent's strategic approach.
Stifel maintained a Buy rating on Nuvalent shares, raising the price target to $115 from $103, reflecting confidence in the upcoming Phase 1 data update for NVL-655.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.